Acute Myeloid Leukemia Clinical Trial
Official title:
Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Verified date | August 2019 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to determine the complete remission/complete remission with incomplete recovery of blood counts (CR/CRi) rate for relapsed and refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients.
Status | Completed |
Enrollment | 37 |
Est. completion date | August 3, 2016 |
Est. primary completion date | April 27, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - • World Health Organization (WHO)-confirmed AML, other than Acute Promyelocytic Leukemia (APL) - Age >18 years - White blood cell count (WBC) at initiation of treatment = 10,000/L o If WBC is > 10,000/L patients may be started on an appropriate dose of hydroxyurea (to be determined by the investigators), until WBC < 10,000/L, at which time the hydroxyurea will be discontinued for 12 hours prior to enrollment - Relapsed or refractory (resistant) disease, as defined by standard criteria21: - Relapsed: Bone marrow blasts =5%; reappearance of blasts in the blood; development of extramedullary disease - Refractory (resistant): Failure to achieve Complete Remission (CR) or complete remission with incomplete recovery of blood counts (CRi) in patients who survive =7 days following completion of initial treatment, with evidence of persistent leukemia by blood and/or bone marrow examination - Failure of at least one prior therapy - Eastern Cooperative Oncology Group (ECOG) performance status = 2 (See Appendix D: ECOG Performance Status Scale) - Life expectancy > 2 months - All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist® (RevAssist is a restricted distribution program for receiving lenalidomide) - Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 million International Units per milliliter (mIU/mL) 10 - 14 days prior to study enrollment and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix F: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods - Willing and able to understand and voluntarily sign a written informed consent - Able to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: - • Known or suspected hypersensitivity to azacitidine or mannitol - Patients with advanced malignant hepatic tumors. - Treatment less than four weeks prior to enrollment with other experimental therapies or antineoplastic agents, with the exception of hydroxyurea - Inability to swallow or absorb drug - Prior treatment with lenalidomide for AML - Active opportunistic infection or treatment for opportunistic infection within four weeks of first day of study drug dosing - New York Heart Association Class III or IV heart failure - Unstable angina pectoris - Significant uncontrolled cardiac arrhythmias - Uncontrolled psychiatric illness that would limit compliance with requirements - Known Human immunodeficiency virus (HIV) infection - Graft vs. host disease = grade 2 - Relapse after allogeneic stem cell transplantation prior to post-transplant day 30 - Pregnant or breast feeding females; lactating females must agree not to breast feed while taking lenalidomide - Other medical or psychiatric illness or organ dysfunction or laboratory abnormality which in the opinion of the investigator would compromise the patient's safety or interfere with data interpretation - Laboratory abnormalities: - Either creatinine >2.0 mg/dL or creatinine clearance <30 mL/min - Total bilirubin > 2 x institutional upper limit of normal (ULN) (unless documented Gilbert's syndrome) - Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) > 3 x institutional ULN |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Cancer Center | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver | Celgene |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts | Change in baseline to end of study. To be assessed by standard criteria based on bone marrow examination. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR | Interim assessment after 18 patients (estimated 2 years) and full assessment after 37 patients (estimated 3-4 years) | |
Primary | Overall Response Rate | Change in baseline to end of study. To be assessed by standard criteria based on bone marrow examination | Planned assessment after enrollment of all 37 patients (estimated 3-4 years) | |
Secondary | Response or Remission Duration | Change in baseline to end of study. To be assessed by standard criteria based on bone marrow examination | Depending on outcomes, will initiate this assessment after 2 years and will continue until completion of study, estimated at 4 years | |
Secondary | Toxicity and SAEs Related to Treatment | Change in baseline to end of study. To be measured based on Common Terminology Criteria for Adverse Events (CTCAE) criteria | Will begin assessment with first patient and will continue until completion of study, estimated to be 4 years | |
Secondary | Overall Survival | Change in baseline to end of study | Depending on outcomes, will begin assessment at 2 years and will continue until completion of study, estimated to be at four years | |
Secondary | Progression-free Survival | Change in baseline to end of study. To be assessed by standard criteria based on bone marrow examination | Depending on outcomes, will initiate this assessment after 2 years and will continue until completion of study, estimated at 4 years | |
Secondary | Determine Biomarkers That Predict Response/Toxicity | Change in baseline to end of study. Planned assessments of methylation changes and other biomarkers. Computational biology modeling used to identify biomarkers and predict response. | Three years after initiating study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Active, not recruiting |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |